List view / Grid view
2 May 2014 | By Merck
MSD and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...
1 May 2014 | By Fibrotech Therapeutics Pty Ltd
Fibrotech announced that it has reached an agreement with Shire plc, under which Shire has agreed to purchase Fibrotech for an upfront payment of $75M...
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
30 April 2014 | By Teva
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties...
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
28 April 2014 | By GlaxoSmithKline
GlaxoSmithKline and Medicines for Malaria Venture announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine...
24 April 2014 | By Biogen Idec
Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement...
24 April 2014 | By Boehringer Ingelheim
Hydra Biosciences, Inc. and Boehringer Ingelheim jointly announced that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors...
23 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site...
23 April 2014 | By Pfizer
Pfizer Inc. announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079)...
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
8 April 2014 | By OncoEthix
OncoEthix announced that the interim results from its ongoing Phase I clinical trial of OTX015, in patients with hematologic malignancies, were presented at the annual American Association of Cancer Research...
7 April 2014 | By The European Medicines Agency
In a meeting at the European Medicines Agency on 4 April 2014, the EMA’s Executive Director, Prof. Guido Rasi, and the National Manager of the Australian Therapeutic Goods AdministrationExternal link icon, Prof. John Skerritt, announced that the two regulators have agreed to share the full assessment reports...
7 April 2014 | By Roche
IQuum’s unique products will allow Roche to quickly enter the point of care segment of molecular diagnostics...
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
